Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Cost of Revenue (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Cost of Revenue data on record, last reported at $77.1 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 173.4% year-over-year to $77.1 million; the TTM value through Dec 2025 reached $317.3 million, up 93.34%, while the annual FY2025 figure was $317.3 million, 257.33% up from the prior year.
  • Cost of Revenue reached $77.1 million in Q4 2025 per COLL's latest filing, down from $80.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $80.4 million in Q1 2025 and bottomed at -$38.5 million in Q4 2021.
  • Average Cost of Revenue over 5 years is $40.4 million, with a median of $33.2 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: plummeted 353.46% in 2021, then skyrocketed 298.98% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at -$38.5 million in 2021, then soared by 197.57% to $37.6 million in 2022, then crashed by 45.14% to $20.6 million in 2023, then soared by 36.84% to $28.2 million in 2024, then surged by 173.4% to $77.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $77.1 million in Q4 2025, $80.2 million in Q3 2025, and $79.6 million in Q2 2025.